SHSaher Hamed

Saher Hamed

*This is an algorithmically generated author record based on publicly available information.

Saher Hamed has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Mark Belokopytov

    Department of Research and Development, Remedor Biomed Ltd., Nazareth Illit, Israel

    3 shared publications
  • Paul Y. Liu

    Department of Plastic Surgery, Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island

    3 shared publications
  • Yehuda Ullmann

    Department of Plastic and Reconstructive Surgery, Rambam Health Care Campus, Haifa, Israel

    3 shared publications
  • Aziz Shoufani

    Department of Plastic Surgery Unit, Ha'emek Medical Center, Afula, Israel

    2 shared publications
  • Luc Teot

    Department of Plastic and Reconstructive Surgery and Wound Healing, Lapeyronie, Montpellier, France

    2 shared publications
  • Sadanori Akita

    Affiliations Fukushima Medical University, Fukushima, Japan, Tamaki Aozora Hospital, Tokushima, Japan

    2 shared publications

Latest Publications

  • Topical Erythropoietin Accelerates Wound Closure in Patients with Diabetic Foot Ulcers: A Prospective, Multicenter, Single-Blind, Randomized, Controlled Trial

    by Saher Hamed, Yehuda Ullmann, Mark Belokopytov, Aziz Shoufani, Hoda Kabha, Suher Masri, Muhamad Safadi, Zeev Feldbrin, Leonid Kogan, Danny Kruchevsky, et al.

    The diabetic foot ulcer (DFU) is a major disabling complication of diabetes mellitus. Growing evidence suggests that topical erythropoietin (EPO) can promote wound healing. The aim of this study is to clinically assess the efficacy of a proprietary topical EPO-containing hydrogel for treating DFUs. We conducted a randomized, controlled trial in 20 patients with DFUs. After a 14-day screening period, the DFUs of 20 eligible participants who fulfilled the inclusion criteria were randomly assigned (1:1) to either a 12-week of daily treatment with topical EPO and standard-of-care (SOC) or SOC treatment alone. The DFUs were assessed weekly until week 12. The primary outcome was 75% ulcer closure or higher. After 12 weeks of treatment, 75% ulcer closure was achieved in 6 of the 10 patients whose DFUs were treated with topical EPO and in one of the 8 patients whose DFUs were treated with SOC alone. The mean area of the DFUs that were treated with topical EPO and SOC was significantly smaller than those treated with SOC alone (1.2 ± 1.4 cm 2 vs. 4.2 ± 3.4 cm 2 ; p = 0.023). Re-epithelialization was faster in the topically EPO-treated DFUs than in the SOC-treated DFUs. There were no treatment-related adverse events. We conclude that topical EPO is a promising treatment for promoting the healing of DFUs. Clinical Trial Registration number: NCT02361931.


  • Interim Results of the Remede d'Or Study: A Multicenter, Single-Blind, Randomized, Controlled Trial to Assess the Safety and Efficacy of an Innovative Topical Formulation of Erythropoietin for Treating Diabetic Foot Ulcers

    by Saher Hamed, Mark Belokopytov, Yehuda Ullmann, Muhammad Safadi, Yafit Stark, Aziz Shoufani, Sadanori Akita, Paul Y. Liu, Luc Teot

    Objective: To inform on the interim results of the Remede d'Or study, which is a prospective, multicenter, single-blind, randomized, controlled clinical study on the safety and efficacy of RMD-G1, a topical carbopol-based hydrogel with a fibronectin matrix whose active pharmaceutical ingredient is erythropoietin (EPO), for treating diabetic foot ulcers (DFU). Approach: The trial will comprise 20 patients with type 2 diabetes mellitus with neuroischemic DFUs who will be randomized into two groups: (1) a control group in which standard-of-care (SOC) will be used to treat the DFUs, and (2) a test group in which SOC and RMD-G1 will be used to treat the DFUs. On day 0, all participants will be randomized to receive either RMD-G1 and SOC treatment or SOC alone. The primary endpoint of the study is complete closure of the DFU within the 12-week study period following daily treatments and dressing changes. Results: Interim results reveal that those DFUs which were treated with RMD-G1 responded positively: there was a significant reduction in the wound areas. In contrast, the condition of those DFUs which were treated with only SOC deteriorated. Innovation: To date, no topical therapies with proven efficacy for treating DFUs exist. Topical application of EPO-based RMD-G1 in conjunction with SOC to a DFU accelerates their healing and closure. Conclusions: The interim results of this trial indicate that topical RMD-G1 is a safe adjunctive therapy to SOC, which accelerates the closure of a DFU. RMD-G1 is safe pharmaceutical because EPO has a proven safety profile.


  • EPO topique pour le traitement des plaies du pied diabétique

    by Saher Hamed, Yehuda Ullmann, Mark Belokopytov, Muhammad SafadI, Yafit Stark, Aziz Shoufani, Sadanori Akita, Paul Y. Liu


  • Topical Erythropoietin Treatment Accelerates the Healing of Cutaneous Burn Wounds in Diabetic Pigs Through an Aquaporin-3–Dependent Mechanism

    by Saher Hamed, Yehuda Ullmann, Dana Egozi, Aviad Keren, Essam Daod, Omer Anis, Hoda Kabha, Mark Belokopytov, Manal Ashkar, Rona Shofti, et al.

    We have previously reported that the topical application of erythropoietin (EPO) to cutaneous wounds in rats and mice with experimentally induced diabetes accelerates their healing by stimulating angiogenesis, reepithelialization, and collagen deposition, and by suppressing the inflammatory response and apoptosis. Aquaporins (AQPs) are integral membrane proteins whose function is to regulate intracellular fluid hemostasis by enabling the transport of water and glycerol. AQP3 is the AQP that is expressed in the skin where it facilitates cell migration and proliferation and re-epithelialization during wound healing. In this report, we provide the results of an investigation that examined the contribution of AQP3 to the mechanism of EPO action on the healing of burn wounds in the skin of pigs with experimentally induced type 1 diabetes. We found that topical EPO treatment of the burns accelerated their healing through an AQP3-dependent mechanism that activates angiogenesis, triggers collagen and hyaluronic acid synthesis and the formation of the extracellular matrix (ECM), and stimulates reepithelialization by keratinocytes. We also found that incorporating fibronectin, a crucial constituent of the ECM, into the topical EPO-containing gel, can potentiate the accelerating action of EPO on the healing of the burn injury.